Group 1 - The core point of the article highlights the recent decline in the stock price of New Nuo Wei, which fell by 5.36% to 37.44 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 0.46%, resulting in a total market capitalization of 52.588 billion CNY [1] - New Nuo Wei, officially known as Shiyao Innovation Pharmaceutical Co., Ltd., is based in Shijiazhuang, Hebei Province, and was established on April 5, 2006. The company went public on March 22, 2019, and its main business involves the research, development, production, and sales of functional foods [1] - The revenue composition of New Nuo Wei is primarily from functional foods and raw materials at 88.93%, followed by biopharmaceuticals at 8.91%, and other sources at 2.16% [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Jianxin Fund has a significant position in New Nuo Wei. Jianxin Medical Health Industry Stock A (008923) increased its holdings by 590,300 shares in the third quarter, bringing the total to 1.4473 million shares, which constitutes 4.74% of the fund's net value, ranking it as the seventh-largest holding [2] - Jianxin Medical Health Industry Stock A (008923) was established on December 28, 2021, with a current scale of 702 million CNY. Year-to-date returns are at 41.64%, ranking 1006 out of 4197 in its category; over the past year, returns are 40.12%, ranking 959 out of 4179; and since inception, returns are 39.64% [2]

Group 1 - Newnow (300765.SZ) reported its Q3 2025 results, with 18 institutional investors holding a total of 1.144 billion shares, representing 81.42% of the total share capital [1] - The top ten institutional investors collectively hold 81.17% of the shares, with a decrease of 0.47 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 10 funds increased their holdings, including Huatai-PineBridge Innovation Medicine Mixed A and ICBC Frontier Medical Stock A, with an increase rate of 0.60% [2] - Three public funds reduced their holdings, including China Europe Medical Health Mixed A, with a decrease rate of 0.37% [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.23% [2]

Core Viewpoint - The Hong Kong stock market has shown strong performance in 2025, with the Hang Seng Index and Hang Seng Tech Index rising by 30.40% and 38.02% respectively, reaching new highs [2][4]. Group 1: Market Performance - Since the beginning of 2025, the Hang Seng Index and Hang Seng Tech Index have both reached new highs, indicating a positive market trend [2]. - The Hang Seng Index peaked at 27,058 points and the Hang Seng Tech Index at 6,461 points on September 18, 2025, marking the highest levels since July 2021 and November 2021 respectively [2]. Group 2: Investment Opportunities - The Federal Reserve's decision to restart interest rate cuts has released global liquidity, making the Hong Kong stock market an attractive investment option due to its valuation advantages [5]. - Southbound capital has accelerated its inflow into the Hong Kong market, with a cumulative net purchase exceeding 1.1 trillion HKD in 2025, providing significant liquidity support [9]. Group 3: Policy and Regulatory Environment - The latest Hong Kong Policy Address has introduced multiple measures aimed at boosting the stock market, including the establishment of an "AI Efficiency Enhancement Group" and initiatives to assist mainland tech companies in financing [12][13]. - The government is exploring various measures to optimize the market ecosystem, such as implementing T+1 settlement rules and promoting the return of Chinese concept stocks [16]. Group 4: Sector Focus - The article highlights three key potential sectors under the "Chinese technology narrative": electronics, new materials, and healthcare, emphasizing the importance of domestic substitution and technological innovation [19][21][22]. - Specific funds focusing on these sectors have shown impressive returns, with one fund in the electronics sector achieving a return of +59.01% over the past year [20].

Group 1 - The core point of the news is that Zai Lab Ltd. (泽璟制药) experienced a stock price increase of 5.01%, reaching 101.78 CNY per share, with a total market capitalization of 26.942 billion CNY [1] - Zai Lab, founded on March 18, 2009, specializes in the research, production, and sales of chemical and biological new drugs, with 99.97% of its revenue coming from pharmaceuticals [1] - The trading volume for Zai Lab was 1.68 million CNY, with a turnover rate of 0.64% [1] Group 2 - According to data, a fund under Jianxin Fund holds Zai Lab as one of its top ten heavy positions, specifically Jianxin Medical Health Industry Stock A (建信医疗健康行业股票A), which reduced its holdings by 29,420 shares in the second quarter [2] - The current holding of Jianxin Medical Health Industry Stock A is 338,600 shares, accounting for 4.18% of the fund's net value, making it the sixth-largest heavy position [2] - The fund has achieved a year-to-date return of 50.69% and a one-year return of 41.08%, ranking 404 out of 4,218 and 1,255 out of 3,864 in its category, respectively [2]

Core Insights - The 2025 Autumn Investment Strategy Conference hosted by Jianxin Fund emphasized the theme of "The Power of Trust," with multiple fund managers sharing market insights and future outlooks [1] Group 1: Macro Framework and Equity Investment - The equity investment department believes that the A-share market is currently in a phase of "fundamental pricing uplift," with short-term market disturbances driven by capital flow and overseas policies [2] - The long-term focus should be on "AI+" and other new productivity drivers, with AI industry chains and large financial sectors identified as key investment themes [2] Group 2: Technology Investment - As of the end of August, the Sci-Tech Innovation Board has 589 listed companies with a total market capitalization exceeding 10 trillion yuan, indicating a robust index system that includes both leading firms and innovative SMEs [5] - The manager highlighted three promising areas in the pharmaceutical sector: oncology treatments, weight-loss drugs, and autoimmune diseases, with significant growth potential in the domestic market [5] Group 3: Hong Kong Market Insights - The Hong Kong stock market shows a diverse resonance across sectors such as internet, biomedicine, new consumption, and hard technology, supported by low valuations and policy backing [6] - The proportion of southbound capital holdings has increased from 10% in 2022 to 21% currently, indicating a growing local investment interest [6] Group 4: Multi-Asset and Risk Management - In the context of global economic uncertainty, gold remains a valuable asset, supported by central bank purchases exceeding 1,000 tons for three consecutive years [8] - The fixed income investment manager noted potential downtrends in real estate and exports, suggesting a focus on trading opportunities in interest rate bonds and credit bonds [8] Group 5: Investment Strategies in Low-Rate Environment - The investment team proposed a dual approach of "offense and defense" to enhance investor experience, advocating for diversified asset allocation and dynamic weight adjustments based on macro factors [9] - The use of options strategies is recommended to manage risks in equity assets while allowing for potential gains [9] Group 6: Company Overview - Jianxin Fund, celebrating its 20th anniversary, manages over 900 billion yuan in public funds, offering a comprehensive product system across various asset types [11] - The company aims to transform macroeconomic analysis, industry research, and asset allocation capabilities into deliverable solutions for investors, focusing on long-term returns and service to the real economy [11]